摘要
目的探讨经动脉化疗栓塞术(TACE)联合抗血管生成药的基础上加用程序性死亡受体-1(PD-1)抑制剂治疗中晚期肝细胞癌(HCC)的有效性和安全性。方法收集分析2018年6月至2020年10月在西京医院接受TACE+抗血管生成药+PD-1抑制剂治疗的中晚期HCC患者。收集患者的临床资料,分析客观缓解率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)、总生存期(OS)及相关不良反应(AE),探讨联合治疗的有效性和安全性。结果共纳入35例HCC患者,至随访截止时间,死亡患者17例(48.6%),存活患者18例(51.4%)。患者的中位PFS为8.9月(95%CI:6.3~11.6),中位OS为16.1月(95%CI:11.4~20.9)。总体ORR为60%,疾病控制率(DCR)为85.7%。在接受治疗的35例患者中,9例(25.7%)患者发生2级以上不良反应,经过减少药量和给与对症处理后均好转。结论联合治疗对中晚期HCC患者有一定的治疗效果,且不良反应相对可控。
Objective To analyze the efficacy and safety of transarterial chemoembolization(TACE)combined with anti-angiogenic drugs and programmed death receptor-1(PD-1)inhibitors in the treatment of intermediate/advanced hepatocellular carcinoma(HCC).Methods Patients treated with TACE+anti-angiogenic drugs+PD-1 inhibitors who were hospitalized in Department of Gastroenterology in Xijing hospital from June 2018 to October 2020 were enrolled.The basic clinical characteristics,objective response rate(ORR),disease control rate(DCR),progression-free survival(PFS),overall survival(OS)and related adverse reactions(AEs)of the patients were collected to explore the efficacy and safety of combined treatment.Results A total of 35 patients were enrolled.At the end of follow-up,17 patients(48.6%)had died and 18 patients(51.4%)were still alive.The median PFS was 8.9 months(95%CI:6.3-11.6)and the median OS was 16.1 months(95%CI:11.4-20.9).The overall ORR was 60.0%and the disease control rate(DCR)was 85.7%.Among the 35 patients who received treatment,9 patients(25.7%)had adverse reactions(AEs)above grade two.The adverse reactions improved after reducing the dosage and/or receiving symptomatic treatment.Conclusion Combination therapy has a certain therapeutic effect on patients with intermediate/advanced HCC,and the adverse reactions are relatively controllable.
作者
丁晓鹏
帖君
余嘉豪
任鹏伟
宣国云
马硕怡
郭长存
韩英
周新民
DING Xiao-peng;TIE Jun;YU Jia-hao;REN Peng-wei;XUAN Guo-yun;MA Shuo-yi;GUO Chang-cun;HAN Ying;ZHOU Xin-min(Department of Gastroenterology,Xijing Hospital,Air Force Medical University,Xi’an 710000,China)
出处
《肝脏》
2022年第3期277-280,291,共5页
Chinese Hepatology
关键词
肝细胞癌
TACE
PD-1抑制剂
回顾性研究
Hepatocellular carcinoma
Transarterial chemoembolization
PD-1 inhibitors
Retrospective study
